2023
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study
Menzies-Gow A, Bourdin A, Chupp G, Israel E, Hellqvist Å, Hunter G, Roseti S, Ambrose C, Llanos J, Cook B, Corren J, Colice G. Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma The NAVIGATOR study. Annals Of Allergy Asthma & Immunology 2023, 131: 343-348.e2. PMID: 37263380, DOI: 10.1016/j.anai.2023.05.028.Peer-Reviewed Original ResearchConceptsExacerbation-related hospitalizationsHealthcare utilizationUncontrolled asthmaNAVIGATOR studyAsthma-related healthcare utilizationEffect of tezepelumabPatient healthcare utilizationRecipients of placeboThymic stromal lymphopoietinHealth-related qualityIntensive care daysHuman monoclonal antibodySubcutaneous tezepelumabAsthma controlAsthma exacerbationsLung functionSpecialist visitsEmergency departmentCare daysOverall burdenTezepelumabMAIN OUTCOMEPlaceboAmbulance transportHospitalization
2021
Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR
Korn S, Bourdin A, Chupp G, Colice G, Ambrose C, Kmita K, Llanos-Ackert J, Molfino N, Cook B. Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR. 2021, oa1198. DOI: 10.1183/13993003.congress-2021.oa1198.Peer-Reviewed Original Research